Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valiant LaboratoriesNSE:VALIANTLAB +0.02%52 EV-to-EBIT is 126.67 as of Jul. 28, 2026, which is 336% above its 10-year median of 29.07. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 52/100 and a GF Value™ of ₹101.39 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 691 Drug Manufacturers companies, Valiant Laboratories ranks worse than 95.22% on this metric.
The historical rank and industry rank for Valiant Laboratories's EV-to-EBIT or its related term are showing as below:
NSE:VALIANTLAB'
s EV-to-EBIT Range Over the Past 10 Years
Min: -749.96 Med: 29.07 Max: 388.54
Current: 126.67
During the past 6 years, the highest EV-to-EBIT of Valiant Laboratories was 388.54. The lowest was -749.96. And the median was 29.07.
NSE:VALIANTLAB's EV-to-EBIT is ranked worse than 95.22% of 691
companies
in the Drug Manufacturers industry
Industry Median: 15.42
vs NSE:VALIANTLAB: 126.67
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Valiant Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was ₹2,934 Mil.
Valiant Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valiant Laboratories EV-to-EBIT Related Terms
Valiant Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's EV-to-EBIT falls into.
Valiant Laboratories's current Enterprise Value is ₹3,400 Mil.
Valiant Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valiant Laboratories (NSE:VALIANTLAB) has a EV-to-EBIT of 126.67 as of Jul. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Valiant Laboratories and its competitors. This is 336% above median its historical median of 29.07. According to the industry distribution chart, Valiant Laboratories ranks #658 out of 691 companies in the Drug Manufacturers industry, placing it in the top 95.2%.
Is Valiant Laboratories' EV-to-EBIT too high?
Valiant Laboratories' current EV-to-EBIT of 126.67 is 336% above median its 10-year median of 29.07. The Drug Manufacturers industry median EV-to-EBIT is 15.42. Valiant Laboratories' value of 126.67 is 721.5% above this industry median. Based on the distribution chart, Valiant Laboratories ranks #658 out of 691 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Valiant Laboratories has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #658 out of 691 companies for EV-to-EBIT. This places Valiant Laboratories in the lower half of its industry. The industry median EV-to-EBIT is 15.42. Valiant Laboratories' value of 126.67 is 721.5% above this benchmark. While the company's 10-year median is 29.07 vs. the industry median of 15.42, Valiant Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.42, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current EV-to-EBIT of 126.67 is 721.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current EV-to-EBIT is 126.67, which is 336% above median its own 10-year median of 29.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹101.39, compared to a current price of ₹61.51 — trading 39.3% below its estimated fair value. The current EV-to-EBIT is 126.67, which is 336% above median its 10-year median of 29.07 and 721.5% above the Drug Manufacturers industry median of 15.42. Valiant Laboratories' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current EV-to-EBIT is 126.67 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹61.51 is trading 39.3% below its estimated GF Value™ of ₹101.39.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
EV-to-EBIT: 126.67 (336% above median its 10-year median of 29.07)
GF Value™: ₹101.39 vs. price of ₹61.51 (39.3% below fair value)
Industry Position: 721.5% above the Drug Manufacturers median (#658 of 691)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
52GF Score
Get the complete analysis for NSE:VALIANTLAB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
